Successful therapy of bosentan-refractory pulmonary arterial hypertension (PAH) with inhalative iloprost

Keihan Ahmadi-Simab; P. Lamprecht; W. L. Gross

Successful therapy of bosentan-refractory pulmonary arterial hypertension (PAH) with inhalative iloprost

Keihan Ahmadi-Simab^*, P. Lamprecht, W. L. Gross

^*Corresponding author for this work

Clinic of Rheumatology

5 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis. High vascular resistance in PAH arises from an imbalance between vasodilatory mediators (prostacyclin, NO) and vasoconstrictive mediators (endothelin, thromboxane A-2). Inhaled iloprost and the dual endothelin receptor antagonist bosentan have recently been shown to be effective in controlled clinical trials. Our case report demonstrates that patients with bosentan-refractory PAH can be successfully treated with iloprost inhalation.

Original language	English
Journal	Clinical and Experimental Rheumatology
Volume	23
Issue number	3
Pages (from-to)	402-403
Number of pages	2
ISSN	0392-856X
Publication status	Published - 05.2005

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{32caf98a392b446c92e4049f98553365,

title = "Successful therapy of bosentan-refractory pulmonary arterial hypertension (PAH) with inhalative iloprost",

abstract = "Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis. High vascular resistance in PAH arises from an imbalance between vasodilatory mediators (prostacyclin, NO) and vasoconstrictive mediators (endothelin, thromboxane A-2). Inhaled iloprost and the dual endothelin receptor antagonist bosentan have recently been shown to be effective in controlled clinical trials. Our case report demonstrates that patients with bosentan-refractory PAH can be successfully treated with iloprost inhalation.",

author = "Keihan Ahmadi-Simab and P. Lamprecht and Gross, {W. L.}",

year = "2005",

month = may,

language = "English",

volume = "23",

pages = "402--403",

journal = "Clinical and Experimental Rheumatology",

issn = "0392-856X",

number = "3",

}

TY - JOUR

T1 - Successful therapy of bosentan-refractory pulmonary arterial hypertension (PAH) with inhalative iloprost

AU - Ahmadi-Simab, Keihan

AU - Lamprecht, P.

AU - Gross, W. L.

PY - 2005/5

Y1 - 2005/5

N2 - Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis. High vascular resistance in PAH arises from an imbalance between vasodilatory mediators (prostacyclin, NO) and vasoconstrictive mediators (endothelin, thromboxane A-2). Inhaled iloprost and the dual endothelin receptor antagonist bosentan have recently been shown to be effective in controlled clinical trials. Our case report demonstrates that patients with bosentan-refractory PAH can be successfully treated with iloprost inhalation.

AB - Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis. High vascular resistance in PAH arises from an imbalance between vasodilatory mediators (prostacyclin, NO) and vasoconstrictive mediators (endothelin, thromboxane A-2). Inhaled iloprost and the dual endothelin receptor antagonist bosentan have recently been shown to be effective in controlled clinical trials. Our case report demonstrates that patients with bosentan-refractory PAH can be successfully treated with iloprost inhalation.

UR - http://www.scopus.com/inward/record.url?scp=20444486938&partnerID=8YFLogxK

M3 - Journal articles

C2 - 15971433

AN - SCOPUS:20444486938

SN - 0392-856X

VL - 23

SP - 402

EP - 403

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

IS - 3

ER -

Successful therapy of bosentan-refractory pulmonary arterial hypertension (PAH) with inhalative iloprost

Abstract

Research Areas and Centers

UN SDGs

Other files and links

Fingerprint

Cite this